Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer A Systematic Review and Meta-analysis

被引:500
作者
Biagi, James J. [1 ]
Raphael, Michael J. [2 ]
Mackillop, William J. [1 ,2 ,3 ]
Kong, Weidong [2 ]
King, Will D. [3 ]
Booth, Christopher M. [1 ,2 ]
机构
[1] Queens Univ, Dept Oncol, Kingston, ON K7L 5P9, Canada
[2] Queens Univ, Div Canc Care & Epidemiol, Canc Res Inst, Kingston, ON K7L 5P9, Canada
[3] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON K7L 5P9, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 22期
基金
加拿大健康研究院;
关键词
III COLON-CANCER; STAGE-II; PUBLICATION BIAS; RECTAL-CANCER; FLUOROURACIL; LEUCOVORIN; THERAPY; ANGIOGENESIS; RADIOTHERAPY; OXALIPLATIN;
D O I
10.1001/jama.2011.749
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown. Objective To determine the relationship between time to AC and survival outcomes via a systematic review and meta-analysis. Data Sources MEDLINE (1975 through January 2011), EMBASE, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched to identify studies that described the relationship between time to AC and survival. Study Selection Studies were only included if the relevant prognostic factors were adequately described and either comparative groups were balanced or results adjusted for these prognostic factors. Data Extraction Hazard ratios (HRs) for overall survival and disease-free survival from each study were converted to a regression coefficient (beta) and standard error corresponding to a continuous representation per 4 weeks of time to AC. The adjusted beta from individual studies were combined using a fixed-effects model. Inverse variance (1/SE2) was used to weight individual studies. Publication bias was investigated using the trim and fill approach. Results We identified 10 eligible studies involving 15 410 patients (7 published articles, 3 abstracts). Nine of the studies were cohort or population based and 1 was a secondary analysis from a randomized trial of chemotherapy. Six studies reported time to AC as a binary variable and 4 as 3 or more categories. Meta-analysis demonstrated that a 4-week increase in time to AC was associated with a significant decrease in both overall survival (HR, 1.14; 95% confidence interval [CI], 1.10-1.17) and disease-free survival (HR, 1.14; 95% CI, 1.10-1.18). There was no significant heterogeneity among included studies. Results remained significant after adjustment for potential publication bias and when the analysis was repeated to exclude studies of largest weight. Conclusion In a meta-analysis of the available literature on time to AC, longer time to AC was associated with worse survival among patients with resected colorectal cancer.
引用
收藏
页码:2335 / 2342
页数:8
相关论文
共 46 条
  • [1] *ADJ ONL, DEC MAK TOOLS HLTH C
  • [2] Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based Study
    Ahmed, Shahid
    Ahmad, Imran
    Zhu, Tong
    Arnold, Florence P.
    Anan, Ghadeer Faiz
    Sami, Amer
    Yadav, Sunil K.
    Alvi, Riaz
    Haider, Kamal
    [J]. DISEASES OF THE COLON & RECTUM, 2010, 53 (10) : 1432 - 1438
  • [3] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [4] Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients:: Final results of GERCOR c96.1
    Andre, Thierry
    Quinaux, Emmanuel
    Louvet, Christophe
    Colin, Philippe
    Gamelin, Erik
    Bouche, Olivier
    Achille, Emmanuel
    Piedbois, Pascal
    Tubiana-Mathieu, Nicole
    Boutan-Laroze, Arnaud
    Flesch, Michel
    Lledo, Gerard
    Raoul, Yves
    Debrix, Isabelle
    Buyse, Marc
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3732 - 3738
  • [5] [Anonymous], 1998, MODERN EPIDEMIOLOGY, DOI DOI 10.1002/(SICI)1097-0258(20000330)19:63.0.CO
  • [6] 2-V
  • [7] [Anonymous], SYST TREATM WAIT TIM
  • [8] Bayraktar UD, CANCER, DOI [10.1002/cncr.25720, DOI 10.1002/CNCR.25720]
  • [9] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [10] Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
    Berglund, A.
    Cedermark, B.
    Glimelius, B.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (02) : 400 - 402